Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

• DOI: 10.1186/s12879-022-07693-9
• Publication Date: 2022-08-29T11:02:55Z
• Authors: Shao-Jun Zhang; Yan Yang; Wen-Wen Sun; Zhong-Shun Zhang; He-Ping Xiao; Yu-Ping Li; Zhe-Min Zhang; Lin Fan
• Keywords: Bedaquiline; Culture conversion; Regimen; Refractory (planetary science); Extensively drug-resistant tuberculosis; Multi-drug-resistant tuberculosis

Refractory rifampicin-resistant/multidrug resistant/extensively-drug resistant tuberculosis (RR/MDR/XDR-TB) were defined as patients infected with Mycobacterium (MTB) to rifampicin(RR-TB), or at least rifampicin and isoniazid (MDR-TB) added fluoroquinolones (FQs) one of second line injectable agents (XDR-TB), a patient for whom an effective regimen (fewer than 4 due adverse events (AEs) multiple drug resistances) cannot be developed. To compare the effectiveness safety bedaquiline (BDQ)-containing BDQ-free regimens treatment refractory RR/MDR/XDR-TB.Patients RR/MDR/XDR-TB receiving BDQ-containing (BDQ group, n = 102) (non-BDQ 100) satisfied included criteria strictly in this retrospective historical control study across East China. Culture conversion, outcome, cavity closing rate, AEs compared between two groups.The baseline characteristics involved all possible aspects well balanced groups (p > 0.05). conversion rates BDQ group month 3 (89.2% vs. 66.0%), 6 (90.2% vs 72.0%), 9 (91.2% 12 (94.1% 65.0%) significantly higher those non-BDQ < 0.001). Similar results observed rate (19.6% 8.0%, p 0.0) (39.2% 15.0%, Patients had more success 0.001; cure 69.6% 45.0%; complete treatment, 22.5% 18.0%; success, 92.2% 63.0%); use combined Linezolid Clofazimine Cycloserine identified independent predictors no culture reversion (P similarly reported 26.5% 19.0% 0.2).BDQ-containing resulted better outcomes similar relative pulmonary RR/MDR/XDR-TB.